COMMUNIQUÉS West-GlobeNewswire

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
03/09/2026
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee. Effective September 1, 2026, in [...]
Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
03/09/2026
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek [...]
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
03/09/2026
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present [...]
FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats
03/09/2026
Silver Spring, Md, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets and revised the EUA for Nitenpyram Tablets, [...]
Ipsen - Août 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
03/09/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - August 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
03/09/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
GENFIT organise un événement virtuel avec un leader d’opinion (KOL) consacré au diagnostic de la MASH le 9 septembre 2026
03/09/2026
Les présentations mettront en avant l’utilité clinique et le potentiel commercial à long terme de la plateforme propriétaire NIS de GENFIT, une technologie de diagnostic non invasive pour la MASH Lille (France), [...]
GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
03/09/2026
Presentations will highlight the clinical utility and long-term commercial opportunity of GENFIT’s proprietary NIS platform, a non-invasive diagnostic technology for MASH Lille (France), Cambridge (Massachusetts, United [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026
03/09/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
03/09/2026
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Hi Rasmus Raises $50 Million from Updata Partners to Accelerate Its Mission
03/09/2026
After growing to serve 1,000+ organizations in 90 countries without outside capital, Hi Rasmus will accelerate its next stage of growth while remaining founder-led and centered on helping care teams focus on the child [...]
Curia Celebrates Expansion of Albuquerque Facility with Ribbon-Cutting Ceremony
03/09/2026
ALBANY, N.Y., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the grand opening of its expanded campus in Albuquerque [...]
Curia célèbre l’agrandissement de son site d’Albuquerque lors d’une cérémonie d’inauguration
03/09/2026
ALBANY, New York, 03 sept. 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), une organisation de premier plan à l´échelle mondiale spécialisée dans la recherche, le développement et la fabrication, a annoncé aujourd’ [...]
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
03/09/2026
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI [...]
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
03/09/2026
NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Claris Bio to Participate in Upcoming Investor Conferences
03/09/2026
JERSEY CITY, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc. , a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited [...]
Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference
03/09/2026
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) , a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance [...]
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
03/09/2026
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program ARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and [...]
Adneuris Therapeutics to Present at PAINWeek 2026
03/09/2026
Adneuris will share new abuse potential data for cebranopadol that demonstrates that its abuse potential may be lower than schedule IV pain drugs Previously announced Phase 3 studies have demonstrated that the Company’s [...]

Pages